Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis by Chouri, Eleni et al.
lable at ScienceDirect
Journal of Autoimmunity xxx (2018) 1e9Contents lists avaiJournal of Autoimmunity
journal homepage: www.elsevier .com/locate/ jaut immSerum microRNA screening and functional studies reveal miR-483-5p
as a potential driver of ﬁbrosis in systemic sclerosis
Eleni Chouri a, b, Nila H. Servaas a, b, Cornelis P.J. Bekker a, b, Alsya J. Affandi a, b,
Marta Cossu a, b, Maarten R. Hillen a, b, Chiara Angiolilli a, b, Jorre S. Mertens a, b,
Lucas L. van den Hoogen a, b, Sandra Silva-Cardoso a, b, Maarten van der Kroef a, b,
Nadia Vazirpanah a, b, Catharina G.K. Wichers a, b, Tiago Carvalheiro a, b,
Soﬁe L.M. Blokland a, b, Barbara Giovannone b, c, Laura Porretti d, Wioleta Marut a, b,
Barbara Vigone e, Joel A.G. van Roon a, b, Lorenzo Beretta e, Marzia Rossato a, b, f, 1,
Timothy R.D.J. Radstake a, b, *, 1
a Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
b Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
c Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
d Flow Cytometry Service, Clinical Chemistry and Microbiology Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan,
Italy
e Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
f Department of Biotechnology, University of Verona, Verona, Italya r t i c l e i n f o
Article history:
Received 9 October 2017
Received in revised form
21 December 2017
Accepted 21 December 2017
Available online xxx
Keywords:
Systemic sclerosis
Circulating microRNAs
miR-483-5p
Fibrosis* Corresponding author. University Medical Centre
3584 CX, Utrecht, The Netherlands.
E-mail address: t.r.d.j.radstake@umcutrecht.nl (T.R
1 These authors contributed equally.
https://doi.org/10.1016/j.jaut.2017.12.015
0896-8411/© 2018 Elsevier Ltd. All rights reserved.
Please cite this article in press as: E. Chouri,
ﬁbrosis in systemic sclerosis, Journal of Autoa b s t r a c t
Objective: MicroRNAs (miRNAs) are regulatory molecules, which have been addressed as potential bio-
markers and therapeutic targets in rheumatic diseases. Here, we investigated the miRNA signature in the
serum of systemic sclerosis (SSc) patients and we further assessed their expression in early stages of the
disease.
Methods: The levels of 758 miRNAs were evaluated in the serum of 26 SSc patients as compared to 9
healthy controls by using an Openarray platform. Three miRNAs were examined in an additional cohort
of 107 SSc patients and 24 healthy donors by single qPCR. MiR-483-5p expression was further analysed in
the serum of patients with localized scleroderma (LoS) (n¼ 22), systemic lupus erythematosus (SLE)
(n¼ 33) and primary Sj€ogren's syndrome (pSS) (n¼ 23). The function of miR-483-5p was examined by
transfecting miR-483-5p into primary human dermal ﬁbroblasts and pulmonary endothelial cells.
Results: 30 miRNAs were signiﬁcantly increased in patients with SSc. Of these, miR-483-5p showed
reproducibly higher levels in an independent SSc cohort and was also elevated in patients with
preclinical-SSc symptoms (early SSc). Notably, miR-483-5p was not differentially expressed in patients
with SLE or pSS, whereas it was up-regulated in LoS, indicating that this miRNA could be involved in the
development of skin ﬁbrosis. Consistently, miR-483-5p overexpression in ﬁbroblasts and endothelial
cells modulated the expression of ﬁbrosis-related genes.
Conclusions: Our ﬁndings showed that miR-483-5p is up-regulated in the serum of SSc patients, from the
early stages of the disease onwards, and indicated its potential function as a ﬁne regulator of ﬁbrosis in
SSc.
© 2018 Elsevier Ltd. All rights reserved.Utrecht, Heidelberglaan 100,
.D.J. Radstake).
et al., SerummicroRNA screen
immunity (2018), https://do1. Introduction
Systemic sclerosis (SSc) is a rare, systemic autoimmune disorder
characterized by vascular damage, immune activation and ﬁbrosis
of the skin and/or internal organs [1]. Even if the pathogenesis ofing and functional studies reveal miR-483-5p as a potential driver of
i.org/10.1016/j.jaut.2017.12.015
E. Chouri et al. / Journal of Autoimmunity xxx (2018) 1e92SSc still remains elusive, increasing evidence suggests that micro-
vascular injury and endothelial cell activation are the earliest
events in the evolution of the disease [2]. The complex interplay
between altered endothelial cells and immune cells inﬁltrating the
tissues results in the secretion of inﬂammatory cytokines and
proﬁbrotic mediators, leading to myoﬁbroblast transition and
culminating in excessive deposition of extracellular matrix (ECM),
deﬁned as ﬁbrosis, the hallmark of SSc [3e5]. Activated myoﬁbro-
blasts in ﬁbrotic tissue can derive from different precursors
including activated ﬁbroblasts, pericytes, ﬁbrocytes, epithelial cells
and endothelial cells, and are characterized by de novo expression
of a-smooth muscle actin (aSMA) [6].
Recently, microRNAs (miRNAs) were proposed as possible novel
players in SSc ﬁbrosis, being capable of modulating several ﬁbrotic-
related genes [7,8]. MiRNAs constitute a class of short non-coding
RNAs (19e24 nucleotides) that regulate gene expression at the
post-transcriptional level. Beside their intracellular function, miR-
NAs are also present in biological ﬂuids, where they circulate bound
to protein complexes or enclosed in extracellular vesicles, including
exosomes [9]. It has been demonstrated that miRNAs embedded in
exosomes are involved in cell-to-cell communication by trans-
ferring their content into the recipient cells [9,10]. Furthermore,
circulating miRNAs are often indicated as potential biomarkers and
therapeutic targets in several diseases, since they are highly stable
molecules and their aberrant expression frequently reﬂects the
pathophysiology of diseases [11,12]. MiRNAs have been shown to be
altered in the serum of SSc patients, implicating them as possible
diagnostic biomarkers for SSc and potential players in the disease
pathogenesis [7,13,14].
Hitherto, the knowledge on circulating miRNAs in SSc is limited
and a broad proﬁling of circulating miRNAs is lacking. Moreover,
the expression of secretory miRNAs in early SSc patients, who do
not yet present with skin ﬁbrosis, has not been explored thus far.
Identifying molecular changes at the early stages is of utmost
importance, as an understanding of the pathophysiological path-
ways leading up to disease could open novel avenues for thera-
peutic intervention before the actual onset of ﬁbrosis.
Here, we present a comprehensive proﬁling of 758 miRNAs in
the serum of SSc patients. MiR-483-5p was demonstrated to be
consistently upregulated in two independent SSc cohorts and
showed high expression before the onset of ﬁbrosis. Moreover,
functional experiments indicated the potential implication of miR-
483-5p in the modulation of ﬁbrosis.
2. Material & methods
2.1. Patients
Blood from patients and sex- and age-matched healthy controls
(HC) was obtained from the University Medical Center Utrecht in
the Netherlands and the Scleroderma Unit of the Fondazione IRCCS
Policlinico of Milan in Italy. All patients signed a consent form
approved by the local institutional review boards, prior to partici-
pation in the study. Samples and clinical information were treated
anonymously immediately after collection. Patients fulﬁlling the
ACR/EULAR 2013 classiﬁcation criteria [15] were classiﬁed in rela-
tion to the extent of skin ﬁbrosis as limited cutaneous (lcSSc) or
diffuse cutaneous SSc (dcSSc) [16]; patients fulﬁlling the classiﬁ-
cation criteria without skin ﬁbrosis will be referred to as non-
cutaneous SSc (ncSSc) throughout the manuscript. Additionally,
early SSc (eaSSc) subjects were deﬁned as patients presenting with
Raynaud's phenomenon (RP) and SSc-speciﬁc autoantibodies and/
or typical nailfold videocapillaroscopy (NVC) abnormalities [17].
The presence of interstitial lung disease (ILD) was identiﬁed as
typical involvement of the lung parenchyma>5% on high resolutionPlease cite this article in press as: E. Chouri, et al., SerummicroRNA screen
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diffusing capacity for carbon monoxide (DLco)< 80% of predicted
values [19].
Two separate cohorts were recruited for the current study
(Discovery and Validation Cohort) at the University Medical Center
Utrecht and the Scleroderma Unit of Fondazione IRCCS Policlinico
of Milan. Early SSc patients were also included in the validation
cohort. Demographics and clinical characteristics of the patients are
depicted in Table 1.
2.2. Blood collection and RNA extraction
Blood was collected in a Vacutainer® SST II tube (BD Vacutainer)
and serum was isolated after centrifugation at 1500g for 10min at
room temperature and stored at 80 C prior to use. Serum RNA
was extracted from 200 ml of serum using the miRcury RNA Isola-
tion kit for Bioﬂuids (Exiqon), according to the manufacturer's in-
structions. During extraction, 300 pg of a non-human synthetic
miRNA (Arabidopsis thaliana ath-miR-159a) was added to each
sample as a spike-in to monitor the technical variability during the
isolation and for subsequent data normalization.
RNA from cells was isolated using the Allprep Universal Kit
(Qiagen), according to the manufacturer's instructions. The con-
centration of RNA was determined using a Qubit 2.0 ﬂuorimeter
(Invitrogen) and the Qubit RNA HS Assay Kit (Molecular Probes, Life
Technologies).
2.3. MiRNA proﬁling
The screening of 758 miRNAs in the Discovery cohort was per-
formed by TaqMan RT-qPCR on an OpenArray platform (Life-
Technologies) according to manufacturer's instructions with minor
adjustments. 2.5 ml of isolated serum RNA was reverse-transcribed
by using the miRNA megaplex RT primer pools (LifeTechnologies).
cDNA was pre-ampliﬁed using the Megaplex PreAmp Primer pools
in the presence of the TaqMan PreAmp Master mix (Life Technol-
ogies), by using the following thermal cycler conditions: 95 C for
10min, 55 C for 2min, 72 C for 2min and 16 cycles of 95 C for
15 s and 60 C for 4min and one single cycle of 96 C for 10min. The
miRNA OpenArray proﬁling was performed on the ampliﬁed cDNA
diluted 1:40 in 0.1x TE (pH8.0), by using the Taqman OpenArray
master mix on the QuantStudio 12k ﬂex Real-Time PCR system
(LifeTechnologies). The Relative Quantiﬁcation method of the
GeneExpression Suite Software (ThermoFisher) was applied to
analyze the data by using the comparative threshold cycle method
(Crt). Low expressed miRNAs were excluded from the analysis: Crt
was set at 27 maximum and only miRNAs with high ampliﬁcation
quality (>1.24) were taken into consideration. The expression of
each miRNAwas calculated after normalization on the levels of the
exogenous spike-in ath-miR-159a and expressed as Fold Change
(FC) as compared to the control samples. MiRNA proﬁling data have
been deposited in NCBI's Gene Expression Omnibus (GSE) and are
accessible through GEO Series accession number GSE108918.
2.4. MiRNA and gene expression analysis
The validation of miRNA expression in serumwas performed by
single Taqman miRNA RealTime-quantitative PCR (RT-qPCR) assays
(LifeTechnologies). Brieﬂy, 2.5 ml of serum RNA was reverse-
transcribed using the speciﬁc microRNA assays (ath-miR159a; ID
000338, has-miR-501-3p; ID 002435, has-miR-483-5p; ID 002338,
U6 snRNA; ID 001973, Life Technologies) and measured with the
speciﬁc TaqMan assay on the QuantStudio 12k ﬂex System, in the
presence of the TaqMan Fast Advanced Master mix (Life-
Technologies), following manufacturer's instructions. MiRNAing and functional studies reveal miR-483-5p as a potential driver of
i.org/10.1016/j.jaut.2017.12.015
Table 1
Demographics and clinical characteristics of the donors included in the study.
Discovery Cohort Validation Cohort
Patient group (n) HC(9) ncSSc(8) lcSSc(9) dcSSc(9) HC (24) ncSSC(26) lcSSc(35) dcSSc(29) eaSSc(17)
Age (yr.) 53(49e55) 49(37e52) 63(54e67) 63(54e66) 56(46e62) 58(49e66) 60(49e69) 50(45e57) 48(37e72)
Female (n, %) 6 (67%) 8 (100%) 6 (67%) 5 (56%) 22 (92%) 25 (96%) 33 (94%) 20 (69%) 16 (94%)
ANA (n pos, %) e 6 (75%) 9 (100%) 8 (89%) e 25 (96%) 32 (91%) 27 (93%) 16 (94%)
ACA (n pos, %) e 3 (38%) 2 (22%) 3 (33%) e 16 (62%) 17 (49%) 2 (6.9%) 10 (59%)
Scl70 (n pos, %) e 2 (25%) 4 (44%) 2 (22%) e 3 (12%) 12 (34%) 14 (48%) 3 (18%)
mRSS e 0 7 (5e8) 12 (8e15) e 0 4 (2e5) 11 (6e18) 0
ILD e 0 2 (22%) 7 (78%) e 4 (15%) 10 (29%) 15 (52%) 0
Disease Duration e 3 (2e7) 4 (2e5) 12 (7e20) e 7 (2e15) 16 (5e23) 8 (2e16) e
Values reported indicate the number (n) of patients and the median for each parameter (Interquartile Range (IQR)), if not otherwise indicated. Yr., years; ANA, antinuclear
antibodies; pos, positivity; ACA, anticentromere antibodies; Scl70, antitopoisomerase antibodies; mRSS, modiﬁed Rodnan Skin score; ILD, Interstitial Lung disease; HC, healthy
controls; ncSSc, non-cutaneous SSc; lcSSc, limited cutaneous SSc; dcSSc, diffuse cutaneous SSc; eaSSc, early SSc.
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threshold cycle method (Ct) after normalization to the spike-in ath-
miR-159a. The relative fold change (FC) of the control samples was
set at 1 and was used to calculate the fold change of the target
miRNAs in patients or treated cells (FC¼ 2^ -DDCt, where
DDCt¼DCt sample - DCt reference).
Expression of protein-coding genes was analyzed by real-time
quantitative-PCR (RT-qPCR) using a 4 ng retrotranscribed RNA
with iScript reverse transcriptase kit (Bio-Rad). Reactions were
conducted using the SybrSelect mastermix with 500 nM speciﬁc
primer pairs on a QuantStudio 12k ﬂex (Life Technologies). RT-qPCR
data were normalized to the expression of GUSB and analyzed us-
ing the comparative threshold cycle method as described for
miRNAs. All primers used are listed in the Supplementary Table 1.
2.5. Exosome isolation and exosomal RNA extraction
Serum was centrifuged at 3000g for 15min at 4 C. Exosomes
were isolated from 250 ml serum by precipitation using the Exo-
quick solution (Systems Biosciences), according to the manufac-
turer's protocol. After exosome precipitation, 300 pg of the spike-in,
ath-miR-159a, was added to each sample during the exosomal RNA
extraction (exoRNA). ExoRNA was isolated according to the manu-
facturer's protocol (Systems Biosciences).
2.6. Fibroblast and HPAEC culture and transfection
Primary dermal ﬁbroblasts were obtained as discarded material
after cosmetic surgery from anonymous donors who gave prior
informed consent for the use of material in research. Dermal ﬁ-
broblasts were isolated using the Whole Skin Dissociation Kit
(Miltenyi Biotech), following the manufacturer protocol. Brieﬂy,
biopsies with diameter of 3 4mm were digested overnight at
37 C and processed with the gentleMACS Dissociator (Miltenyi
Biotech) to obtain a single cell suspension. Fibroblasts were
cultured in DMEM medium (Life Technologies) containing 10%
heat-inactivated fetal bovine serum (FBS, Biowest) and used in
passages between 3 and 5. Human pulmonary artery endothelial
cells (HPAEC, ThermoFisher) were cultured in endothelial basal
medium (EBM-2 Basal Medium, Lonza) containing manufacturer-
recommended supplemental growth factors (EGM-2 Bullet-kit)
supplemented with 10% FBS, and used in passages 3e4.
50.000 ﬁbroblasts or HPAEC were seeded in 12-well plates in
their respective culturemedium and after 24 h culturemediumwas
replaced with Opti-MEM I Reduced Serum Medium (Life-
Technologies). Fibroblasts were transfected with 100 nM miR-483-
5p mimic or miR-scramble control (Ambion) using the transfection
reagent DharmaFECT-1 (Dharmacon) for 24 h, while HPAECs were
transfected with 20 nM miR-483-5p mimic or miR-scramblePlease cite this article in press as: E. Chouri, et al., SerummicroRNA screen
ﬁbrosis in systemic sclerosis, Journal of Autoimmunity (2018), https://docontrol for 6 h. After removal of transfection medium, cells were
recovered overnight in complete medium. Before stimulation, cells
were pre-starved for 24 h in DMEMwith 1% FBS or for 3 h in EBM-2
with 0.1% FBS and subsequently were either left untreated or
stimulated respectively either with 10 ng/ml TGFb1 (Biolegend) or
TGFb2 (R&D systems) for 24 or 48 h. Cells were lysed in RLTplus
buffer (Qiagen) supplemented with beta-mercaptoethanol for RNA
isolation.
2.7. Statistical analysis
ExpressionSuite Software (Life Technologies) was used for the
analysis of miRNA proﬁling data. Independent t-test on the
comparative Ct method (DDCt) was performed on ExpressionSuite
software and differences were considered signiﬁcant at the level of
p< .05 (uncorrected p-value). GraphPad Prism 6.0 Software or IBM
SPSS 21 Software was used for the subsequent analysis in the study.
Kruskal-Wallis and Dunn's multiple comparison post hoc tests,
Mann-Whitney U test and Wilcoxon signed rank test were applied
to compare data that were not normally distributed as indicated.
Spearman's rho was used to assess correlations. Differences were
considered statistically signiﬁcant at p< .05.
The miRWalk 2.0 database (http://zmf.umm.uni-heidelberg.de/
apps/zmf/mirwalk2/custom.html) was used to retrieve the miRNA
targets and pathway enrichment analysis was performed on the
ToppGene Suite website (https://toppgene.cchmc.org/enrichment.
jsp). Pathways were considered signiﬁcantly enriched at p< .05
adjusting the false discovery rate (FDR) using Benjamini-Hochberg.
3. Results
3.1. The proﬁle of circulating miRNAs is altered in the serum of SSc
patients
The expression level of 758 miRNAs and 3 small-nuclear RNAs
was evaluated in the serum of healthy donors (n¼ 10) and SSc
patients, either without any evident skin involvement (ncSSc,
n¼ 8), or with limited cutaneous ﬁbrosis (lcSSc, n¼ 9), or diffuse
cutaneous SSc (dcSSc, n¼ 9). Twenty-nine serum miRNAs and one
small nuclear RNA (snRNA-U6) were differentially expressed in at
least one group of patients as compared to the healthy controls in
the discovery cohort (Table 2).
We then sought to validate the three highly dysregulated short-
RNAs that showed a signiﬁcant change in all the three SSc subsets,
namely miR-483-5p, miR-501-3p and snRNA-U6 (Fig. 1A). We
evaluated their expression in an independent SSc validation cohort,
encompassing 107 SSc patients and 24 healthy donors. Here, the
elevated expression of miR-483-5p and snRNA-U6 was replicated
in SSc patients, while the levels of miR-501-3p were noting and functional studies reveal miR-483-5p as a potential driver of
i.org/10.1016/j.jaut.2017.12.015
Table 2
MiRNAs differentially expressed in the serum of SSc patients.
miRNA ncSSc lcSSc dcSSc
FC p value FC p value FC p value
snRNA-U6 4.968 .030 5.160 .014 5.496 .003
miR-483-5p 2.087 .022 2.730 .041 3.145 .009
miR-501-3p 1.994 .021 3.401 .000 2.377 .001
miR-423-5p 1.100 .715 2.685 .011 1.952 .097
miR-223* 1.936 .140 2.290 .031 1.753 .222
miR-320b 1.875 .023 2.422 .005 1.670 .121
miR-23a 1.642 .124 2.137 .012 1.562 .071
miR-324-3p 1.758 .033 2.048 .006 1.428 .105
miR-491 1.639 .081 2.165 .001 1.484 .086
miR-532-3p 1.811 .080 2.151 .002 1.422 .187
miR-345 0.995 .680 2.199 .010 1.398 .220
miR-133a 1.832 .044 2.051 .033 0.973 .943
miR-22* 1.496 .143 2.028 .012 0.985 .785
miR-410 0.473 .041 0.914 .579 0.718 .379
miR-15b 0.806 .681 1.048 .539 0.485 .013
miR-331 0.665 .224 0.872 .591 0.480 .018
miR-103 0.717 .383 0.779 .174 0.460 .003
miR-30b 0.719 .304 0.374 .149 0.452 .043
let-7d 0.646 .227 0.744 .596 0.448 .006
miR-26b 0.876 .762 0.811 .123 0.444 .003
miR-181a 0.854 .666 1.011 .985 0.444 .017
miR-28 0.773 .488 0.742 .667 0.418 .014
miR-30c 0.282 .053 0.789 .259 0.409 .005
miR-144* 0.816 .311 0.624 .071 0.402 .006
miR-374 0.815 .721 0.653 .048 0.352 .002
miR-374-5p 0.638 .376 0.680 .089 0.329 .007
miR-191 0.941 .581 0.981 .773 0.297 .006
miR-142-3p 0.689 .087 0.948 .759 0.257 .003
miR-26a 0.613 .135 0.736 .094 0.211 .001
miR-409-3p 0.300 .040 0.540 .508 0.188 .025
The expression of 758miRNAs was analyzed in RNA extracted from the serum of SSc
patients and healthy controls in the discovery cohort, using the OpenArray platform.
The expression of each miRNA was calculated as Fold Changes (FC) as compared to
the mean of the healthy control group. MiRNAs were considered differentially
expressed with a FC of 2 or 0,5 and a p-value of <0,05 in at least one patient-
group vs healthy controls (indicated in bold); ncSSc, non-cutaneous SSc; lcSSc,
limited cutaneous SSc; dcSSc, diffuse cutaneous SSc.
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483-5p and snRNA-U6 was also present in eaSSc patients
(Fig. 1C), demonstrating that these short-RNAs are altered before
the appearance of evident ﬁbrosis.3.2. MiR-483-5p is speciﬁcally up-regulated in scleroderma
patients
In order to verify whether the increased levels of miR-483-5p
and snRNA-U6 were speciﬁc for SSc patients, their expression was
evaluated in the serum of patients with other autoimmune dis-
eases, either presenting ﬁbrotic features, such as localized sclero-
derma (LoS) (n¼ 22), or systemic non-ﬁbrotic diseases, such as
systemic lupus erythematosus (SLE) (n¼ 33) and primary Sj€ogren's
Syndrome (pSS) (n¼ 23) (Supplementary Table 2).
Similar to what we observed in SSc patients, miR-483-5p was
also signiﬁcantly increased in the serum of LoS patients (Fig. 2A)
whereas the increase of snRNA-U6 was speciﬁc to SSc (Fig. 2B).
These results suggest that miR-483-5p is speciﬁc for conditions
marked by skin ﬁbrosis. In addition, both SSc cohorts showed that
miR-483-5p levels were the highest in dcSSc patients, i.e. the group
with the most extensive skin ﬁbrosis. In agreement with this, we
also observed that in the validation cohort miR-483-5p expression
correlated with the modiﬁed Rodnan Skin Score (mRSS) in dcSSc
particularly (r¼ 0.405 p¼ .029, Supplementary Fig. 1). Further-
more, miR-483-5p is predicted to regulate target genes enriched in
pathways related to SSc pathogenesis and linked to ﬁbrosis, such asPlease cite this article in press as: E. Chouri, et al., SerummicroRNA screen
ﬁbrosis in systemic sclerosis, Journal of Autoimmunity (2018), https://doPDGF signaling or insulin growth factor signaling (Supplementary
Table 3). In the light of these observations as well as the fact that
miR-483-5p has been associated with ﬁbrosis previously [20], we
further investigated its potential role in SSc pathogenesis.
3.3. Circulating miR-483-5p is embedded in serum exosomes and
stable over time
To investigate whether miR-483-5p could be implicated in cell-
to-cell communication during SSc pathogenesis - frequently
orchestrated by exosomal trafﬁcking - we analyzed whether the
pool of circulating miR-483-5p in the serum of SSc patients was
stored in exosomes. MiR-483-5p was highly enriched in the exo-
some fraction compared to the exosome-depleted serum (FC> 30,
p< .0001) (Fig. 3A). Similar to the results obtained in total serum,
the levels of miR-483-5p were signiﬁcantly higher in the exosomes
of both eaSSc (FC¼ 3.8 p¼ .020) and SSc patients (FC¼ 3.7
p¼ .004) compared to healthy controls (Fig. 3B). Furthermore, the
treatment of serum with RNase, prior to RNA isolation, did not
affect the levels of miR-483-5p detected in either patients or con-
trols, thus conﬁrming that the circulating miR-483-5p pool is
protected inside extracellular vesicles (Fig. 3C). In addition, miR-
483-5p showed stable expression in patients and healthy controls
over multiple samplings of the same individuals over a period of 15
months (Fig. 3D). All these observations indicated that miR-483-5p
is stably embedded in exosomes, suggesting that miR-483-5p
might play a role in SSc pathogenesis by affecting target cells
implicated in the ﬁbrotic process, e.g. ﬁbroblasts and endothelial
cells.
3.4. MiR-483-5p modulates the expression of ﬁbrosis-related genes
in ﬁbroblasts and endothelial cells
As a proof of concept to investigate the possible role of miR-483-
5p in ﬁbrosis development, we mimicked the uptake of miR-483-
5p by transfecting it into ﬁbroblasts and endothelial cells, as po-
tential recipient cells, and evaluated the expression of genes
implicated in myoﬁbroblast transition and collagen production.
Upon TGFbeta (TGFb) stimulation, a known ﬁbrotic mediator in
SSc, overexpression of miR-483-5p in ﬁbroblasts (Fig. 4A) led to the
up-regulation of Collagen-type IV Alpha 1 and Alpha 2 Chain
(Col4A1 and Col4A2) and down-regulation of Collagen-type I Alpha
2 Chain (Col1A2) (Fig. 4B). In line with what was observed in ﬁ-
broblasts, Col4A1 and Col4A2 expression were also induced in
TGFb-stimulated endothelial cells upon miR-483-5p transfection,
while Col1A2 was reduced (Fig. 4D). Additionally, the expression of
aSMA and SM22A, two known myoﬁbroblast differentiation
markers, were both induced transcriptionally in miR-483-5p
transfected endothelial cells (Fig. 4D). Noteworthy, miR-483-5p
uptake signiﬁcantly elevated the transcriptional levels of aSMA,
SM22A, Col4A1 and Col4A2 also in unstimulated endothelial cells
(Supplementary Fig. 2A). Moreover, miR-483-5p overexpression
signiﬁcantly lowered the expression of Fli-1, a suppressor of
collagen transcription (Supplementary Fig. 2A). On the contrary
Col5A1, Col5A2 and two genes not primarily involved in extracel-
lular matrix deposition, namely beta-2-microglobulin (B2M) and
Interleukin-6 (IL6) were not signiﬁcantly changed either in ﬁbro-
blasts or in endothelial cells (Supplementary Figs. 2B and C). Of
note, the upregulatory effect of miR-483-5p on Col4A1 and SM22A
was evident even at low doses, at overexpression levels (0.02 nM,
FC~20) within the range observed in the circulation of SSc patients
(Supplementary Fig. 3). Moreover, the modulations observed could
be speciﬁcally attributed to the biological effect of miR-483-5p, as
they were not evident when overexpressing at the same dose a
non-targeting microRNA (miR-Scr) or miR-618, a miRNA previouslying and functional studies reveal miR-483-5p as a potential driver of
i.org/10.1016/j.jaut.2017.12.015
Fig. 1. MiR-483-5p and snRNA-U6 are higher expressed in SSc serum. The expression of miR-483-5p, snRNA-U6 and miR-501-3p were analyzed in RNA extracted from the serum
of donors included in the discovery cohort using the OpenArray platform (A) and in the validation cohort by quantitative RT-qPCR (B). The expression of the miRNAs was also
assessed in the serum of early SSc patients collected simultaneously with the validation cohort (C). The expression is presented as fold change (FC) as compared to the mean
expression of healthy donors. HC, Healthy controls; eaSSc, early SSc; ncSSc, non-cutaneous SSc; dcSSc, difusse cutaneous SSc; lcSSc, limited cutaneous SSc. *p < .05, **p < .01,
***p < .001.
E. Chouri et al. / Journal of Autoimmunity xxx (2018) 1e9 5shown to be dysregulated in the immune compartment of SSc pa-
tients [21], but not reported to be altered in their circulation or in
ﬁbroblast and endothelial cells (Supplementary Fig. 4). Taken
together, these ﬁndings suggest that miR-483-5p can have anPlease cite this article in press as: E. Chouri, et al., SerummicroRNA screen
ﬁbrosis in systemic sclerosis, Journal of Autoimmunity (2018), https://doimpact on ﬁbrosis development by inducing myoﬁbroblast differ-
entiation and an imbalance in collagen production.ing and functional studies reveal miR-483-5p as a potential driver of
i.org/10.1016/j.jaut.2017.12.015
Fig. 2. MiR-483-5p is up-regulated speciﬁcally in scleroderma patients (SSc and LoS) among other autoimmune diseases. The expression of miR-483-5p (A) and snRNA-U6 (B)
were analyzed in the serum of healthy controls (HC), Sj€ogren's syndrome (pSS), systemic lupus erythematosus (SLE), localized scleroderma (LoS) and systemic sclerosis (SSc)
patients by single-assay RT-qPCR. The expression is presented as fold change (FC) as compared to the mean expression of the HC group. ****p < .0001.
Fig. 3. MiR-483-5p is embedded in circulating serum exosomes. The expression of miR-483-5p was assessed in exosomes compared to serum-depleted exosomes (A) and in the
exosomes of SSc patients compared to healthy controls (selected from the validation cohort) after exosome precipitation by Exoquick solution (B). The levels of miR-483-5p were
assessed in the serum of patients and healthy controls after the treatment of serum with RNAse (C). The expression of miR-483-5p was examined in the serum of HC and SSc
patients in 2 different time points of the same donors over a period of 15 months (D). The expression of miR-483-5p is presented as fold change (FC). *p < .05, **p < .01, ****p < .0001.
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The aetiopathology of systemic sclerosis is poorly understood
and the molecular mechanisms that underlie the excessive ECM
deposition have not been truly identiﬁed yet. Representing a new
class of regulatory molecules, miRNAs have recently been investi-
gated as potential key factors in the pathogenesis of SSc [7,14].
Moreover, the fact that circulating miRNAs can reﬂect the patho-
genic states in autoimmunity suggests these molecules as prom-
ising disease markers and potential therapeutic targets. In the
present study we examined the miRNA signature in the serum of
SSc patients. To our knowledge this is the ﬁrst study investigating a
comprehensive miRNA proﬁling in the serum of SSc patients,
including subjects with or without clinically overt skin ﬁbrosis.
Our proﬁling analysis highlighted that the serum of SSc patients
is markedly different than healthy controls in terms of miRNA
expression, with 30 miRNAs altered in one or more SSc clinical
subtypes. Among them, some miRNAs previously reported in other
studies were included (Supplementary Table 4). Consistent with
this literature, circulating miR-30b, miR-142-3p and miR-150 were
differentially expressed in SSc patients [22e24]. However, miR-Fig. 4. miR-483-5p modulates the expression of ﬁbrotic-related genes in human derm
endothelial cells (HPAEC) were transfected with control non-targeting miRNA (miR-Scr)
quantitative RT-qPCR (N ¼ 3). (B, D) The impact of miR-483-5p overexpression on the mRN
qPCR after 24 h of stimulation with TGFb1 (ﬁbroblasts) or TGFb2 (HPAEC). Results are pre
independent experiments on distinct ﬁbroblast donors or HPAEC. *p < 0,5.
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SSc patients in our study [23,24]. Furthermore, in our discovery
cohort miR-92a was not differentially expressed and let-7a did not
reach statistical signiﬁcance, despite being identiﬁed as dysregu-
lated in SSc previously [25,26]. One possible explanation for the
altered expression pattern of the aforementioned miRNAs may lie
in ethnic differences, as demonstrated in previous studies [27].
Another plausible reason is the lack of appropriate validation in
additional groups of patients or the variability in the clinical fea-
tures of the participants [28], especially when analysing patients
with a high degree of heterogeneity as in SSc.
In our study, the elevated expression of circulating miR-483-5p
and snRNA-U6 was reproducible in an independent cohort of SSc
patients in all the disease subsets, conﬁrming that these two mol-
ecules are robustly dysregulated in SSc patients regardless of the
genetic background and the disease heterogeneity. In addition,
miR-483-5p demonstrated stable expression levels over time in
multiple samplings of patients and healthy controls, suggesting the
validated miR-483-5p as a potential disease marker. Preliminary
analysis based on the Receiver Operating Characteristic (ROC)
Analysis indicated a high predictive ability of miR-483-5p as SScal ﬁbroblasts and endothelial cells. Human dermal ﬁbroblasts or pulmonary artery
or miR-483-5p mimic. (A, C) miR-483-5p transfection efﬁciency was measured by
A expression of ﬁbrotic genes and myoﬁbroblast-related markers was assessed by RT-
sented as the fold change (FC) compared to the control miR-src transfections of 6e7
ing and functional studies reveal miR-483-5p as a potential driver of
i.org/10.1016/j.jaut.2017.12.015
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60% of SSc patients exceeding a potential optimal cut-off of normal
levels (Supplementary Fig. 5). However, the high variability of miR-
483-5p among individuals or the methodological standardization
issues in using miRNAs for clinical diagnosis, might limit the utility
of miR-483-5p as a biomarker. Adequate studies should be con-
ducted to verify the potential of miR-483-5p as a (early) marker for
SSc, as well as its prognostic value, also in combination with other
clinical parameters.
Noteworthy, miR-483-5p was speciﬁcally up-regulated both in
localized scleroderma and systemic sclerosis, but not in other sys-
temic autoimmune diseases like systemic lupus erythematosus and
primary Sj€ogren's syndrome, indicating that this miRNA could be
implicated in the ﬁbrosis characterizing scleroderma patients.
Additionally, as previously reported in patients with adenocarci-
noma [29], our study demonstrated that miR-483-5p is circulating
in SSc serum enclosed in exosomes. Interestingly, miR-483-5p is
encoded in an intron of the imprinted insulin-like growth factor
(IGF2) gene [30], which is increased in SSc-lung ﬁbroblasts [31].
IGF2 is associated with SSc-related pulmonary ﬁbrosis and triggers
an increase in ECM production in SSc ﬁbroblasts as compared to
normal ﬁbroblasts [31]. Since miR-483-5p is co-expressed together
with its host gene IGF2 [30], is embedded in exosomes and is
predicted to regulate ﬁbrosis-related signalling, we hypothesize
that it may be involved in a feed-forward loop that promotes ECM
deposition and hence the development of ﬁbrosis in SSc.
Supporting our hypothesis, the overexpression of miR-483-5p in
ﬁbroblasts and endothelial cells regulated the expression of
ﬁbrosis-related genes. Notably, high levels of miR-483-5p induced
collagen IV (Col4A1 and Col4A2) production in ﬁbroblasts and
endothelial cells. Col4, which is a primary collagen in the basement
membranes around blood vessels and in the dermoepidermal
junction in the skin, is reported to be dysregulated in SSc. More
speciﬁcally, Col4 is up-regulated in the serum of SSc patients and
positively correlates with mRSS [32] and it is also higher expressed
in endothelial cells obtained from SSc-lungs compared to control
lungs [33]. Together with our data, this suggests that miR-483-5p
could play a pro-ﬁbrotic role in SSc by inducing Col4.
Conﬁrming the role of miR-483-5p as a potential ﬁbrotic driver,
miR-483-5p overexpression in endothelial cells enhanced the
transcriptional levels of aSMA and SM22A, two known myoﬁbro-
blast differentiation markers, indicating that the cells undergo
myoﬁbroblast transition. In addition, miR-483-5p lowered the
expression of Fli-1, a negative regulator of ECM that is known to be
suppressed in SSc skin [34]. In contrast, high levels of miR-483-5p
inhibited collagen 1 (Col1) production. This suggests a more com-
plex molecular mechanism underlying the role of miR-483-5p in
SSc, which may neglect the machinery maintaining collagen ho-
meostasis. In view of these ﬁndings, we propose that miR-483-5p
may act as a regulator of ﬁbrogenesis, which enhances the levels
of Col4 and promotes myoﬁbroblast differentiation, whereas it in-
hibits Col1. Due to its dual activity, one can speculate that altered
levels of miR-483-5p result in an imbalance of the ﬁbrotic processes
in ﬁbroblasts and endothelial cells and possibly affect the physio-
logical equilibrium in ECM deposition, thus favoring the transition
to the disease state.
Previous literature demonstrates that miRNA-enriched exo-
somes are involved in crosstalk between cells and might act as
signaling mediators in physiological and pathological processes
[9,35]. As an example, cardiac ﬁbroblast-derived exosomal miRNAs
can be transported to cardiomyocytes, leading to cellular hyper-
trophy [34]. Thus based on these evidences, we propose that the
altered levels of circulating exosomal miR-483-5p may be taken up
by activated ﬁbroblasts and endothelial cells, already in the early
disease stages. Our results showed that the uptake of the miRNA inPlease cite this article in press as: E. Chouri, et al., SerummicroRNA screen
ﬁbrosis in systemic sclerosis, Journal of Autoimmunity (2018), https://dothese cells may affect the physiological equilibrium in ECM depo-
sition and contribute to the establishment of the ﬁbrotic phase of
the disease. These observations suggest the need for additional
investigations focused on the possible transfer of miR-483-5p from
circulating vesicles to affected cells and its impact in the evolution
of the disease.
5. Conclusions
Comprehensive proﬁling demonstrated that circulating miRNAs
are signiﬁcantly altered in the serum of SSc patients compared to
healthy individuals. Of note, miR-483-5p was up-regulated in the
serum of SSc patients, either presenting with or without evident
skin ﬁbrosis. This study proposes that miR-483-5p serves as a new
molecular marker for early stages of the disease that is implicated
in the molecular circuitry leading to ﬁbrosis in SSc.
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